Your browser is no longer supported. Please, upgrade your browser.
Settings
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E21.03 EPS (ttm)5.72 Insider Own2.60% Shs Outstand60.15M Perf Week4.00%
Market Cap7.23B Forward P/E10.59 EPS next Y11.35 Insider Trans-2.57% Shs Float58.50M Perf Month11.26%
Income355.30M PEG1.21 EPS next Q2.65 Inst Own92.70% Short Float2.21% Perf Quarter-0.88%
Sales1.43B P/S5.05 EPS this Y460.60% Inst Trans-0.01% Short Ratio1.80 Perf Half Y-14.96%
Book/sh28.39 P/B4.23 EPS next Y13.97% ROA9.30% Target Price174.82 Perf Year-8.53%
Cash/sh7.08 P/C16.97 EPS next 5Y17.42% ROE21.50% 52W Range95.80 - 160.00 Perf YTD10.24%
Dividend- P/FCF20.90 EPS past 5Y44.40% ROI13.80% 52W High-24.88% Beta1.22
Dividend %- Quick Ratio3.10 Sales past 5Y50.10% Gross Margin93.30% 52W Low25.46% ATR3.78
Employees920 Current Ratio3.20 Sales Q/Q9.80% Oper. Margin37.20% RSI (14)57.89 Volatility3.02% 2.98%
OptionableYes Debt/Eq1.27 EPS Q/Q1.50% Profit Margin24.80% Rel Volume1.50 Prev Close121.43
ShortableYes LT Debt/Eq1.25 EarningsFeb 07 AMC Payout0.00% Avg Volume715.16K Price120.19
Recom1.80 SMA204.08% SMA508.84% SMA200-7.72% Volume1,072,284 Change-1.02%
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
May-11-16Reiterated UBS Buy $162 → $168
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Jan-23-17 07:13PM  Why Cramer expects nothing good to come of Fitbit at CNBC
Jan-22-17 01:27PM  3 Biotechs Likely to Be Acquired in 2017 at Motley Fool
Jan-19-17 03:34PM  Jazz Pharmaceuticals Plc: Leads amongst peers with strong fundamentals
09:50AM  Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
Jan-18-17 04:20PM  Jazz Rebuffs Concerns Of Generic Sleep Drug Amid Patent Litigation +11.28%
11:05AM  Wednesdays Top Biopharma Winners
09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
09:15AM  FDA Approves Generic of Jazz Pharma's Sleep Drug at Investopedia
09:13AM  Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers
08:44AM  Jazz Begins Phase III Study for Label Expansion of Defitelio
06:10AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jan-17-17 05:28PM  Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
05:16PM  FDA approves generic version of Jazz Pharma's sleep disorder drug Reuters
04:02PM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients PR Newswire
Jan-11-17 03:21PM  9 Stocks Trading Below the Peter Lynch Value
Jan-10-17 08:15AM  Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine Accesswire
Jan-09-17 05:00PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
11:11AM  Start the New Year off Right with 3 Best Biotech Stocks at Motley Fool
Jan-05-17 10:26AM  Here's Why Jazz Pharmaceuticals PLC Fell Out of Tune and Lost 22% in 2016 at Motley Fool
Jan-04-17 05:49PM  Industrial Companies Showing Good Potential for 2017
Jan-03-17 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 9 PR Newswire
Jan-02-17 09:03AM  4 Top Stocks on Sale This Winter at Motley Fool
Dec-30-16 05:16PM  Gurus and Insiders Invest in Industrial and Medical Companies
Dec-27-16 10:54AM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : December 27, 2016
Dec-26-16 07:33AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 26, 2016
Dec-21-16 10:35AM  What Are Analysts Saying about Horizon Pharma?
Dec-19-16 09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-18-16 07:06AM  3 Top Healthcare Stocks You've Been Overlooking at Motley Fool
Dec-16-16 01:56PM  ETFs with exposure to Jazz Pharmaceuticals Plc : December 16, 2016
Dec-07-16 01:49PM  Hedge Funds Arent Letting Their Money Stay At Wyndham Worldwide Corporation (WYN) at Insider Monkey
07:29AM  Hedge Funds Are Dumping Jazz Pharmaceuticals plc Ordinary Shares (JAZZ) at Insider Monkey
Dec-05-16 12:16PM  ETFs with exposure to Jazz Pharmaceuticals Plc : December 5, 2016
Nov-29-16 07:51AM  Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Nov-28-16 04:05PM  Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy PR Newswire
Nov-25-16 01:14PM  Gurus Invest in Undervalued Biotech Stocks
Nov-17-16 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
Nov-14-16 08:15AM  Blog Coverage Gilead Sciences Hepatitis B Drug Vemlidy Approved by European Medicines Agency Accesswire
Nov-10-16 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire
12:36PM  ETFs with exposure to Jazz Pharmaceuticals Plc : November 10, 2016
Nov-09-16 10:04AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +6.03%
09:07AM  The Market In 5 Minutes: Trump Victory Spooks Stocks
08:48AM  Jazz Pharma (JAZZ) Q3 Earnings Top, Sales Lag Estimates
07:10AM  5 Sectors Poised to Benefit From Donald Trump's Victory at Motley Fool
02:39AM  Edited Transcript of JAZZ earnings conference call or presentation 8-Nov-16 9:30pm GMT
Nov-08-16 05:33PM  Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:16PM  Jazz misses Street 3Q forecasts
04:12PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2016 Financial Results PR Newswire
08:40AM  2 Stocks to Watch After the Market Closes on Election Day
07:07AM  Q3 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Nov-07-16 04:05PM  Jazz Pharmaceuticals to Present New Data at the Annual ASH Meeting PR Newswire
07:52AM  Drug Stock Earnings to Watch on Nov 8: JAZZ, VRX, TBPH, OPHT
Nov-04-16 07:00AM  Trader's Daily Notebook: For a Decline, It Sure Was Smooth +6.57%
Nov-02-16 01:54PM  Pricing Concerns Push Jazz Pharmaceuticals PLC Down 10% in October at Motley Fool
Nov-01-16 08:32AM  Jazz Pharma (JAZZ) Q3 Earnings: A Disappointment in Store?
Oct-25-16 04:05PM  Jazz Pharmaceuticals to Report 2016 Third Quarter Financial Results on November 8, 2016 PR Newswire
Oct-24-16 01:35PM  Top 5 valuable Pharma stocks : October 24, 2016
Oct-20-16 10:52AM  3 Healthcare Stocks That Are Looking Cheap at Motley Fool
Oct-09-16 01:12PM  These Are US Hedge Funds Favorite European Stocks at Insider Monkey
Oct-04-16 09:12AM  Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos
Oct-03-16 08:30AM  Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017 PR Newswire
Sep-28-16 10:05AM  Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial
Sep-27-16 01:30PM  Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast at Barrons.com
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
Sep-26-16 04:25PM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
04:05PM  Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea PR Newswire
Sep-23-16 09:07AM  The Cheapest Stocks in Biotech at Motley Fool
Sep-21-16 01:04PM  Next Year Setting Up To Be Smooth For Jazz Pharmaceuticals
11:05AM  How Analysts See Horizon Compared to Its Peers
Sep-19-16 12:59PM  Understanding Valeants Improved Valuation Multiple
Sep-10-16 12:09PM  3 Mid-Cap Healthcare Stocks You Can Buy Right Now at Motley Fool
Sep-08-16 06:53PM  Halvorsen Bought 13 New Holdings in 2nd Quarter
Sep-07-16 04:05PM  Jazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-06-16 04:00PM  3 Hottest Cancer Biotech Acquisition Targets After Medivation at Forbes
Aug-29-16 08:32AM  Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Aug-27-16 06:36PM  Here Are All The Big Biotech Mergers In 2016
Aug-26-16 09:05AM  Hedge Funds Are Obesely Overweight These 5 Mid-caps at Insider Monkey
Aug-25-16 03:52PM  Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'
Aug-24-16 12:03PM  ETFs with exposure to Jazz Pharmaceuticals Plc : August 24, 2016
Aug-23-16 09:04AM  Pfizers Medivation Acquisition: What You Need to Know
Aug-16-16 08:18AM  4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer at Motley Fool
Aug-12-16 02:29PM  ETFs with exposure to Jazz Pharmaceuticals Plc : August 12, 2016
08:25AM  Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas at 24/7 Wall St.
Aug-11-16 03:04PM  Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report
10:06AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
08:08AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : August 11, 2016
Aug-10-16 03:37PM  Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance -6.67%
10:28AM  Jazz Pharmaceuticals Remains On Goldman's Buy List
07:55AM  Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Aug-09-16 11:50PM  Edited Transcript of JAZZ earnings conference call or presentation 9-Aug-16 8:30pm GMT
06:11PM  Jazz misses Street 2Q forecasts
04:22PM  Jazz Pharmaceuticals Misses Earnings, Cuts Guidance
04:12PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results PR Newswire
07:07AM  Q2 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Aug-06-16 08:53AM  4 Specialty Drugmakers Reporting Earnings Next Week
Aug-05-16 07:45AM  Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Aug-02-16 07:15PM  CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation PR Newswire
Jul-29-16 03:27PM  Jazz Financing I Ltd. -- Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected at Moody's
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, a late-stage investigational compound, which is in phase III clinical trail for the treatment of EDS in narcolepsy and obstructive sleep apnea; and JZP-386, a deuterium-modified analog of sodium oxybate that is completed phase I clinical trail for use in patients with narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cox Russell J.EVP & COOJan 18Sale128.754,000515,00047,095Jan 19 06:29 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 17Sale115.9320023,18616,686Jan 18 06:32 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale103.0920020,61816,886Dec 16 05:09 PM
ENRIGHT PATRICK GDirectorDec 02Sale101.8067768,9191,365Dec 06 04:31 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 15Sale112.1920022,43816,925Nov 16 05:11 PM
O'Keefe Kenneth WDirectorNov 14Buy112.4550056,2242,000Nov 15 05:12 PM
O'Keefe Kenneth WDirectorNov 11Buy114.311,500171,4651,500Nov 15 05:12 PM
MILLER MICHAEL PATRICKSVP, US CommercialOct 17Sale118.1620023,63217,125Oct 18 05:14 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 19Sale126.1720025,23417,325Sep 20 05:34 PM
Mulligan SeamusDirectorAug 25Sale128.3227,9683,588,7871,048,008Aug 26 04:24 PM
Treacy PaulSVP, Technical OperationsAug 16Sale137.471,292177,60913,870Aug 18 04:47 PM
MILLER MICHAEL PATRICKSVP, US CommercialAug 15Sale136.4510013,64517,525Aug 16 06:42 PM
Winningham Rick EDirectorAug 15Sale136.4563386,37315,391Aug 17 05:47 PM
Sohn Catherine A.DirectorAug 15Sale136.4563386,3736,116Aug 17 05:41 PM
RIEDEL NORBERT GDirectorAug 15Sale136.4563386,3734,953Aug 17 05:35 PM
McSharry Heather AnnDirectorAug 15Sale136.4568593,4686,076Aug 17 05:31 PM
ENRIGHT PATRICK GDirectorAug 15Sale136.4563386,3732,042Aug 17 05:25 PM
BERNS PAUL LDirectorAug 15Sale136.4563386,3735,234Aug 17 05:20 PM
Smith Karen L.Global Head of R&D and CMOAug 12Buy137.1060883,35614,182Aug 12 04:36 PM
COZADD BRUCE CChairman & CEOAug 09Sale150.001,000150,000299,184Aug 11 04:49 PM
Cox Russell J.EVP & COOAug 09Sale148.664,000594,64051,038Aug 10 04:39 PM
MILLER MICHAEL PATRICKSVP, US CommercialJul 15Sale142.4310014,24317,625Jul 18 07:55 PM
Smith Karen L.Global Head of R&D and CMOJul 13Buy143.6358083,30513,574Jul 13 08:09 PM
MILLER MICHAEL PATRICKSVP, US CommercialJun 15Sale149.6410014,96417,725Jun 16 05:33 PM
Smith Karen L.Global Head of R&D and CMOJun 13Buy149.6155783,33512,994Jun 15 05:17 PM
Mulligan SeamusDirectorMay 24Sale150.2927,9684,203,3391,074,611May 26 05:02 PM
MILLER MICHAEL PATRICKSVP, US CommercialMay 16Sale145.2010014,52017,753May 17 05:56 PM
RIEDEL NORBERT GDirectorMay 16Sale145.2064493,5094,221May 17 05:39 PM
McSharry Heather AnnDirectorMay 16Sale145.20697101,2045,396May 17 05:31 PM
WILSON KAREN JSVP, Finance & PAOApr 25Sale160.0060496,64018,059Apr 27 06:15 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 15Sale145.7910014,57918,792Apr 18 05:04 PM
Cox Russell J.EVP & COOApr 12Sale136.984,000547,92060,470Apr 13 04:29 PM
WILSON KAREN JSVP, Finance & PAOApr 07Sale140.902,161304,48523,670Apr 08 04:43 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale129.1710012,91718,892Mar 16 05:48 PM
COZADD BRUCE CChairman & CEOMar 08Sale126.042,500315,100300,066Mar 09 07:26 PM
Treacy PaulSVP, Technical OperationsFeb 29Sale123.4835443,71215,100Mar 02 05:59 PM
Mulligan SeamusDirectorFeb 23Sale122.7127,9683,431,9041,102,579Feb 24 07:56 PM
COZADD BRUCE CChairman & CEOFeb 09Sale111.372,500278,425281,896Feb 11 05:01 PM